UniProt Q15375 · PDB · AlphaFold · Substrate: pEY · Clone: catalytic domain (aa 579-998)medium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 96.1% | 3.9% | 78.23 | 0.534 |
| 2 | Cabozantinib | 92.9% | 7.1% | 92.73 | 0.751 |
| 3 | Repotrectinib | 85.8% | 14.2% | 84.21 | 0.608 |
| 4 | Selpercatinib | 84.0% | 16.0% | 96.72 | 0.635 |
| 5 | Tivozanib | 83.3% | 16.7% | 92.42 | 0.673 |
| 6 | Crizotinib | 83.0% | 17.0% | 91.39 | 0.581 |
| 7 | Fostamatinib | 82.3% | 17.7% | 96.74 | 0.613 |
| 8 | Gilteritinib | 72.2% | 27.8% | 88.97 | 0.506 |
| 9 | Vandetanib | 68.0% | 32.0% | 95.74 | 0.723 |
| 10 | Defactinib | 66.5% | 33.5% | 92.68 | 0.450 |
| 11 | Ripretinib | 56.9% | 43.1% | 92.95 | 0.674 |
| 12 | Pralsetinib | 48.6% | 51.4% | 93.43 | 0.643 |
| 13 | Canertinib | 48.0% | 52.0% | 96.49 | 0.671 |
| 14 | Afatinib | 39.5% | 60.5% | 98.50 | 0.709 |
| 15 | Dacomitinib | 39.0% | 61.0% | 97.99 | 0.664 |
| 16 | Sunitinib | 38.0% | 62.0% | 91.73 | 0.524 |
| 17 | Lorlatinib | 37.7% | 62.3% | 97.24 | 0.694 |
| 18 | Regorafenib | 35.9% | 64.1% | 95.99 | 0.719 |
| 19 | Sorafenib | 29.3% | 70.7% | 96.72 | 0.776 |
| 20 | Erlotinib | 29.3% | 70.7% | 99.75 | 0.695 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.34
- Epithelial log2(TPM+1): 0.77
- Fold change: -0.42
- Status: No significant change
High-confidence drugs
- Cabozantinib — inh 92.9% · KISS 37.74
- Ponatinib — inh 96.1% · KISS 28.18
- Selpercatinib — inh 84.0% · KISS 27.42
Selectivity landscape vs inhibition on EPHA7
Each point is one of the 92 approved drugs; color = inhibition % on EPHA7.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…